Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2001 Mar;38(3):159–164. doi: 10.1136/jmg.38.3.159

Male breast cancer in Cowden syndrome patients with germline PTEN mutations

J Fackenthal 1, D Marsh 1, A Richardson 1, S Cummings 1, C Eng 1, B Robinson 1, O Olopade 1
PMCID: PMC1734834  PMID: 11238682

Abstract

Cowden syndrome (CS) (OMIM 158350) is a multiple hamartoma syndrome associated with germline mutations in the PTEN tumour suppressor gene. While CS is characterised most commonly by non-cancerous lesions (mucocutaneous trichilemmomas, acral and palmoplantar keratoses, and papillomatous papules), it is also associated with an increased susceptibility to breast cancer (in females) and thyroid cancer, as well as non-cancerous conditions of the breast and thyroid. Here we report two cases of male breast cancer occurring in patients with classical CS phenotypes and germline PTEN mutations. The first subject was diagnosed with CS indicated primarily by mucocutaneous papillomatosis, facial trichilemmomas, and macrocephaly with frontal bossing at the age of 31 years. He developed breast cancer at 41 years and subsequently died of the disease. A PTEN mutation, c.802delG, was identified in this subject, yet none of his family members showed evidence of a CS phenotype, suggesting that this PTEN mutation may be a de novo occurrence. The second subject had a CS phenotype including multiple trichilemmomas and thyroid adenoma, developed male breast cancer at 43 years, and died of the disease at 57 years. He was a carrier of a PTEN mutation c.347-351delACAAT that cosegregated with the CS phenotype in affected family members. These two cases of male breast cancer associated with germline PTEN mutations and the CS phenotype suggest that CS may be associated with an increased risk of early onset male as well as female breast cancer.


Keywords: PTEN; male breast cancer; Cowden syndrome

Full Text

The Full Text of this article is available as a PDF (132.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anan H., Okazaki M., Fujimitsu R., Hamada Y., Sakata N., Nanbu M. Intracystic papillary carcinoma in the male breast. A case report. Acta Radiol. 2000 May;41(3):227–229. doi: 10.1080/028418500127345398. [DOI] [PubMed] [Google Scholar]
  2. Bannayan G. A. Lipomatosis, angiomatosis, and macrencephalia. A previously undescribed congenital syndrome. Arch Pathol. 1971 Jul;92(1):1–5. [PubMed] [Google Scholar]
  3. Bardenstein D. S., McLean I. W., Nerney J., Boatwright R. S. Cowden's disease. Ophthalmology. 1988 Aug;95(8):1038–1041. doi: 10.1016/s0161-6420(88)33066-6. [DOI] [PubMed] [Google Scholar]
  4. Bhagwandeen S. B. Carcinoma of the male breast in Zambia. East Afr Med J. 1972 Feb;49(2):89–93. [PubMed] [Google Scholar]
  5. Boyd J., Rhei E., Federici M. G., Borgen P. I., Watson P., Franklin B., Karr B., Lynch J., Lemon S. J., Lynch H. T. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat. 1999 Jan;53(1):87–91. doi: 10.1023/a:1006030116357. [DOI] [PubMed] [Google Scholar]
  6. Cardone M. H., Roy N., Stennicke H. R., Salvesen G. S., Franke T. F., Stanbridge E., Frisch S., Reed J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998 Nov 13;282(5392):1318–1321. doi: 10.1126/science.282.5392.1318. [DOI] [PubMed] [Google Scholar]
  7. Chen S. T., Yu S. Y., Tsai M., Yeh K. T., Wang J. C., Kao M. C., Shih M. C., Chang J. G. Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer. Breast Cancer Res Treat. 1999 May;55(1):85–89. doi: 10.1023/a:1006142919428. [DOI] [PubMed] [Google Scholar]
  8. Cross D. A., Alessi D. R., Cohen P., Andjelkovich M., Hemmings B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995 Dec 21;378(6559):785–789. doi: 10.1038/378785a0. [DOI] [PubMed] [Google Scholar]
  9. Datta S. R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997 Oct 17;91(2):231–241. doi: 10.1016/s0092-8674(00)80405-5. [DOI] [PubMed] [Google Scholar]
  10. Dawson P. J., Paine T. M., Wolman S. R. Immunocytochemical characterization of male breast cancer. Mod Pathol. 1992 Nov;5(6):621–625. [PubMed] [Google Scholar]
  11. Diehl J. A., Cheng M., Roussel M. F., Sherr C. J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998 Nov 15;12(22):3499–3511. doi: 10.1101/gad.12.22.3499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Easton D. F., Steele L., Fields P., Ormiston W., Averill D., Daly P. A., McManus R., Neuhausen S. L., Ford D., Wooster R. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997 Jul;61(1):120–128. doi: 10.1086/513891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Eng C. Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol. 1998 Mar;12(3):701–710. doi: 10.3892/ijo.12.3.701. [DOI] [PubMed] [Google Scholar]
  14. Evans D. B., Crichlow R. W. Carcinoma of the male breast and Klinefelter's syndrome: is there an association? CA Cancer J Clin. 1987 Jul-Aug;37(4):246–251. doi: 10.3322/canjclin.37.4.246. [DOI] [PubMed] [Google Scholar]
  15. Fargnoli M. C., Orlow S. J., Semel-Concepcion J., Bolognia J. L. Clinicopathologic findings in the Bannayan-Riley-Ruvalcaba syndrome. Arch Dermatol. 1996 Oct;132(10):1214–1218. [PubMed] [Google Scholar]
  16. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676–689. doi: 10.1086/301749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fox S. B., Day C. A., Rogers S. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. J Clin Pathol. 1991 Nov;44(11):960–961. doi: 10.1136/jcp.44.11.960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Furnari F. B., Huang H. J., Cavenee W. K. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 1998 Nov 15;58(22):5002–5008. [PubMed] [Google Scholar]
  19. Gilbert H. D., Plezia R. A., Pietruk T. Cowden's disease (multiple hamartoma syndrome). J Oral Maxillofac Surg. 1985 Jun;43(6):457–460. doi: 10.1016/s0278-2391(85)80056-2. [DOI] [PubMed] [Google Scholar]
  20. Gorlin R. J., Cohen M. M., Jr, Condon L. M., Burke B. A. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet. 1992 Oct 1;44(3):307–314. doi: 10.1002/ajmg.1320440309. [DOI] [PubMed] [Google Scholar]
  21. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A. F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997 Sep 1;57(17):3660–3663. [PubMed] [Google Scholar]
  22. Hanssen A. M., Fryns J. P. Cowden syndrome. J Med Genet. 1995 Feb;32(2):117–119. doi: 10.1136/jmg.32.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Joshi M. G., Lee A. K., Loda M., Camus M. G., Pedersen C., Heatley G. J., Hughes K. S. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996 Feb 1;77(3):490–498. doi: 10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  24. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  25. Longy M., Coulon V., Duboué B., David A., Larrègue M., Eng C., Amati P., Kraimps J. L., Bottani A., Lacombe D. Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J Med Genet. 1998 Nov;35(11):886–889. doi: 10.1136/jmg.35.11.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Longy M., Lacombe D. Cowden disease. Report of a family and review. Ann Genet. 1996;39(1):35–42. [PubMed] [Google Scholar]
  27. Maehama T., Dixon J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998 May 29;273(22):13375–13378. doi: 10.1074/jbc.273.22.13375. [DOI] [PubMed] [Google Scholar]
  28. Mallory S. B. Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin. 1995 Jan;13(1):27–31. [PubMed] [Google Scholar]
  29. Marsh D. J., Coulon V., Lunetta K. L., Rocca-Serra P., Dahia P. L., Zheng Z., Liaw D., Caron S., Duboué B., Lin A. Y. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998 Mar;7(3):507–515. doi: 10.1093/hmg/7.3.507. [DOI] [PubMed] [Google Scholar]
  30. Marsh D. J., Dahia P. L., Caron S., Kum J. B., Frayling I. M., Tomlinson I. P., Hughes K. S., Eeles R. A., Hodgson S. V., Murday V. A. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet. 1998 Nov;35(11):881–885. doi: 10.1136/jmg.35.11.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Marsh D. J., Dahia P. L., Coulon V., Zheng Z., Dorion-Bonnet F., Call K. M., Little R., Lin A. Y., Eeles R. A., Goldstein A. M. Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer. 1998 Jan;21(1):61–69. doi: 10.1002/(sici)1098-2264(199801)21:1<61::aid-gcc8>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  32. Marsh D. J., Dahia P. L., Zheng Z., Liaw D., Parsons R., Gorlin R. J., Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997 Aug;16(4):333–334. doi: 10.1038/ng0897-333. [DOI] [PubMed] [Google Scholar]
  33. Marsh D. J., Kum J. B., Lunetta K. L., Bennett M. J., Gorlin R. J., Ahmed S. F., Bodurtha J., Crowe C., Curtis M. A., Dasouki M. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999 Aug;8(8):1461–1472. doi: 10.1093/hmg/8.8.1461. [DOI] [PubMed] [Google Scholar]
  34. Marsh D. J., Roth S., Lunetta K. L., Hemminki A., Dahia P. L., Sistonen P., Zheng Z., Caron S., van Orsouw N. J., Bodmer W. F. Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res. 1997 Nov 15;57(22):5017–5021. [PubMed] [Google Scholar]
  35. Mathew C. G., Chin K. S., Easton D. F., Thorpe K., Carter C., Liou G. I., Fong S. L., Bridges C. D., Haak H., Kruseman A. C. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature. 1987 Aug 6;328(6130):527–528. doi: 10.1038/328527a0. [DOI] [PubMed] [Google Scholar]
  36. Misra S. P., Misra V., Dwivedi M. Cancer of the breast in a male cirrhotic: is there an association between the two? Am J Gastroenterol. 1996 Feb;91(2):380–382. [PubMed] [Google Scholar]
  37. Mutter G. L., Lin M. C., Fitzgerald J. T., Kum J. B., Baak J. P., Lees J. A., Weng L. P., Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000 Jun 7;92(11):924–930. doi: 10.1093/jnci/92.11.924. [DOI] [PubMed] [Google Scholar]
  38. Myers M. P., Pass I., Batty I. H., Van der Kaay J., Stolarov J. P., Hemmings B. A., Wigler M. H., Downes C. P., Tonks N. K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513–13518. doi: 10.1073/pnas.95.23.13513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nelen M. R., van Staveren W. C., Peeters E. A., Hassel M. B., Gorlin R. J., Hamm H., Lindboe C. F., Fryns J. P., Sijmons R. H., Woods D. G. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997 Aug;6(8):1383–1387. doi: 10.1093/hmg/6.8.1383. [DOI] [PubMed] [Google Scholar]
  40. Salem O. S., Steck W. D. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol. 1983 May;8(5):686–696. doi: 10.1016/s0190-9622(83)70081-2. [DOI] [PubMed] [Google Scholar]
  41. Schrager C. A., Schneider D., Gruener A. C., Tsou H. C., Peacocke M. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol. 1998 Jan;29(1):47–53. doi: 10.1016/s0046-8177(98)90389-6. [DOI] [PubMed] [Google Scholar]
  42. Starink T. M., van der Veen J. P., Arwert F., de Waal L. P., de Lange G. G., Gille J. J., Eriksson A. W. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986 Mar;29(3):222–233. doi: 10.1111/j.1399-0004.1986.tb00816.x. [DOI] [PubMed] [Google Scholar]
  43. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  44. Teng D. H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K. L., Vinson V. L., Gumpper K. L. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997 Dec 1;57(23):5221–5225. [PubMed] [Google Scholar]
  45. Thomas D. B., Jimenez L. M., McTiernan A., Rosenblatt K., Stalsberg H., Stemhagen A., Thompson W. D., Curnen M. G., Satariano W., Austin D. F. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992 Apr 1;135(7):734–748. doi: 10.1093/oxfordjournals.aje.a116360. [DOI] [PubMed] [Google Scholar]
  46. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J. G., Tavtigian S. V., Tulinius H., Ogmundsdottir H. M., Eyfjörd J. E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996 May;13(1):117–119. doi: 10.1038/ng0596-117. [DOI] [PubMed] [Google Scholar]
  47. Thorlacius S., Sigurdsson S., Bjarnadottir H., Olafsdottir G., Jonasson J. G., Tryggvadottir L., Tulinius H., Eyfjörd J. E. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997 May;60(5):1079–1084. [PMC free article] [PubMed] [Google Scholar]
  48. Thyresson H. N., Doyle J. A. Cowden's disease (multiple hamartoma syndrome). Mayo Clin Proc. 1981 Mar;56(3):179–184. [PubMed] [Google Scholar]
  49. Tsou H. C., Teng D. H., Ping X. L., Brancolini V., Davis T., Hu R., Xie X. X., Gruener A. C., Schrager C. A., Christiano A. M. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet. 1997 Nov;61(5):1036–1043. doi: 10.1086/301607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wade T. R. Cowden's disease. Cutis. 1979 Nov;24(5):537–541. [PubMed] [Google Scholar]
  51. Wade T. R., Kopf A. W. Cowden's disease: a case report and review of the literature. J Dermatol Surg Oncol. 1978 Jun;4(6):459–464. doi: 10.1111/j.1524-4725.1978.tb00473.x. [DOI] [PubMed] [Google Scholar]
  52. Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., Said J. W., Isaacs W. B., Sawyers C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246–5250. doi: 10.1073/pnas.95.9.5246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zonana J., Rimoin D. L., Davis D. C. Macrocephaly with multiple lipomas and hemangiomas. J Pediatr. 1976 Oct;89(4):600–603. doi: 10.1016/s0022-3476(76)80397-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES